BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Jerini AG And Bachem AG Announce Collaboration For Icatibant Production


10/19/2005 5:10:30 PM

BERLIN & BUBENDORF, Switzerland--(BUSINESS WIRE)--March 18, 2004--Jerini AG and Bachem AG today announced a collaboration agreement for production and supply of Jerini's lead compound Icatibant. At present, Icatibant is tested in several clinical trials to treat refractory ascites in liver cirrhosis as well as hereditary angioedema. By 2006 Jerini plan to bring Icatibant to market.

"With Bachem we have gained a reliable and experienced partner to secure fast high-quality production of Icatibant. Furthermore, Bachem is well experienced in regulatory affaires and procedures", said Jochen Knolle, PhD, Jerini's head of R&D.

"We are very pleased to contribute to further developing Icatibant by producing the substance and supporting all phases from clinical studies to market introduction. Icatibant for us seems to be a very promising drug compound", said Walter Isler, Head of Marketing and Sales, Bachem AG.

Icatibant, a synthetic decapeptide (peptidomimetic) with a similar structure to bradykinin (BK), is the most potent of the BK receptor antagonists known so far. At present, Icatibant is tested in a Phase II trial in patients with refractory ascites in liver cirrhosis and hereditary angioedema. Available clinical results are very promising. Jerini has been granted orphan drug designation for Icatibant for the treatment of angioedema by the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) as well as by the European Agency for the Evaluation of Medicinal Products (EMEA). Orphan drug designation gives the designated drug several years of market exclusivity.

Under the terms of the agreement, Bachem will supply Jerini with cGMP-produced Icatibant for clinical trials. Bachem will assume the entire process validation including necessary documentation for the registration process. First approval for Icatibant in the indication angioedema is targeted for 2006.

Jerini AG

Jerini AG (www.jerini.com) is a drug discovery and development company based in Berlin, Germany. The company has built a pipeline of several preclinical and two clinical projects (phase II) with its proprietary Peptides-To-Drugs (P2D) discovery platform. P2D addresses extra- and intra-cellular targets and was developed to overcome the limitations of conventional HTS or protein-based discovery approaches. P2D includes massive parallel syntheses and screening of peptide leads, pharmacophore identification and transformation into peptidomimetic and/or small molecule drugs. The peptide lead to a small molecule conversion step is a direct process that does not include any intermediate modifications of the peptide lead. It is supported by medicinal chemistry and cheminformatics and guided by matching the pharmacophore derived from massive peptide SAR data information against a virtual small molecule library. Jerini's platform allows the rapid identification and/or optimization of agonists and antagonists for (difficult) target proteins. The technology has been successfully demonstrated in in-house and partnered programs for highly valuable but difficult targets where conventional methods have failed. Jerini's approach creates value by reducing time and costs and by decreasing attrition rates.

Key Facts: +++ Founded 1994 +++ 86 Employees +++

Executive Board: +++ Prof. Jens Schneider Mergener (CEO) +++ Dr. Jochen Knolle (Head R&D) +++ Dr. Adi Hoess (CBO) +++ Berndt Modig(CFO) +++

Bachem AG

Bachem is an independent, technology-based company, specialized in the production of innovative biochemicals for research purposes and pharmaceutical compounds for the pharma and biotech industries, as well as in the development of optimal manufacturing processes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in its field.

Key Facts: +++ Founded 1971 +++ over 500 Employees +++

Executive Board: +++ Dr. Rolf Nyfeler (CEO) +++ Reto Conrad (CFO)

+++ Dr. Daniel Erne (CTO) +++

Contacts

Jerini AG Dr. Kirsten Jacobs T + 49 - 30 - 97893 - 471 X + 49 - 30 - 97893 - 105 jacobs@jerini.com or

Bachem Holding AG Reto Conrad T +41 - 61 - 935 2333 X +41 - 61 - 935 2324 reto.conrad@bachem.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES